This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
18 Dec 2016

Boehringer Ingelheim and Lilly welcome new recommendation for Jardiance tablets in updated ADA's 2017 Standards

Guidelines include new recommendation to consider the use of Jardiance in people with type 2 diabetes and established cardiovascular disease to reduce the risk of cardiovascular death.

The American Diabetes Association's (ADA) 2017 Standards of Medical Care in Diabetes specifically include a new recommendation to consider the use of Jardiance (empagliflozin) tablets in people with type 2 diabetes and established cardiovascular disease to reduce the risk of cardiovascular death. The updated recommendations, which were published in Diabetes Care, reinforce the critical connection between type 2 diabetes and the increased risk of death due to cardiovascular disease. Jardiance is the first and only type 2 diabetes treatment approved by the FDA to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease and is the only oral type 2 diabetes medicine shown in a clinical trial to provide this life-saving cardiovascular benefit.

People with diabetes are two to four times more likely to develop cardiovascular disease than people without diabetes. Cardiovascular disease is the leading cause of death associated with diabetes, so it is imperative that adults with type 2 diabetes have treatment options that can help reduce this risk.

"Boehringer Ingelheim and Lilly commend the ADA's commitment to addressing the critical connection between type 2 diabetes and increased cardiovascular risk," said Thomas Seck, vice president, Clinical Development and Medical Affairs, Primary Care, Boehringer Ingelheim Pharmaceuticals. "These important new recommendations recognize the latest scientific evidence and highlight the role of Jardiance for reducing the risk of cardiovascular death in people with type 2 diabetes and established cardiovascular disease and represent an important advance for patient care."

The recommendation is based on breakthrough evidence from the landmark EMPA-REG OUTCOME trial, which investigated the effects of Jardiance compared with placebo when added to standard of care type 2 diabetes and cardiovascular medicines in adults with type 2 diabetes and established cardiovascular disease. On 2 December, the FDA approved a new indication for Jardiance to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.

Related News